Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

EXPERT OPINION ON THERAPEUTIC PATENTS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to the critical analysis and commentary on therapeutic patents, emphasizing their impact on drug discovery and development. With an improving reputation reflected in its 2023 Q1 rankings in Drug Discovery and Pharmacology, this journal stands out as a leading source in the fields of pharmacology and medicine, holding significant relevance with a Scopus ranking in the 90th percentile for its contributions in Drug Discovery and a robust position in Pharmacology. Launched in 1991, the journal consistently engages researchers and professionals seeking to stay at the forefront of innovations in therapeutic patents, thus driving advancements in the pharmaceutical landscape. Although it does not offer Open Access, its comprehensive scope and commitment to quality make it an essential resource for those looking to explore the intersection of intellectual property and pharmacological research.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Nucleic Acid Therapeutics is a leading peer-reviewed journal published by Mary Ann Liebert, Inc that focuses on the forefront of research in the fields of biochemistry, drug discovery, genetics, and molecular medicine. With an impressive Q1 ranking across multiple categories, including biochemistry and drug discovery, the journal aims to disseminate innovative findings on nucleic acid-based therapies, their mechanisms, and clinical applications. The journal is dedicated to advancing the understanding of nucleic acids in the development of new therapeutic strategies, appealing to a diverse audience of researchers, professionals, and students alike. Given its commitment to open access publishing, Nucleic Acid Therapeutics ensures that groundbreaking research is accessible, fostering collaboration and dialogue in this critical area of scientific inquiry. Situated in the United States, Nucleic Acid Therapeutics plays a pivotal role in connecting researchers and practitioners in the ever-evolving landscape of molecular medicine and biotechnology.